P03_LSJ-Pylarify_HCA_Redacted.pdf

This Limited Sources Justification document details a contract for the Department of Veterans Affairs (VA) to procure Pylarify (piflutfolastat F-18) Injection from Progenics Pharmaceuticals Inc. The contract covers a base year from 01/01/2026 to 12/31/2026 with an option year from 01/01/2027 to 12/31/2027, involving 120 units of the product. Pylarify is a radioactive diagnostic antigen for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer, intended for patients with suspected metastasis who are candidates for initial definitive therapy. The procurement is being conducted under the Multiple-Award Schedule Program, with Progenics Pharmaceuticals identified as the sole source due to exclusive distribution and marketing rights, and having received FDA approval with a short half-life of only a few hours.